SCHEMBL25035385

SCHEMBL25035385

COCCn1c(=O)c(-c2ccc(NS(=O)(=O)Cc3ccccc3F)c(F)c2)cc2cnc(N)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.45
ERN1 O75460 1/20 0.43
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
STK26 Q9P289 1/20 0.39
STK24 Q9Y6E0 1/20 0.39
SRC P12931 1/20 0.38
BTK Q06187 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BRD4 O60885 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
PIK3CA P42336 2/20 0.37
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357765 0.90 ERN1 (0.43) BRAFERN1STK4STK3SIK2
SCHEMBL22191316 0.90 ERN1 (0.43) BRAFERN1STK4STK3SIK2
SCHEMBL25035557 0.90 BRAF (0.44) BRAFBRD4F2ALOX5APFEN1
SCHEMBL29356454 0.89 ERN1 (0.44) BRAFERN1STK4STK3SIK2
SCHEMBL22191284 0.89 ERN1 (0.44) BRAFERN1STK4STK3SIK2
SCHEMBL25035521 0.84 ERN1 (0.49) BRAFERN1BRD4PIK3CAALOX5AP
SCHEMBL25035558 0.82 BRAF (0.45) BRAFERN1BRD4ALOX5APFEN1
SCHEMBL25035573 0.82 BRAF (0.45) BRAFERN1BRD4ALOX5APFEN1
SCHEMBL22200422 0.82 ERN1 (0.53) BRAFERN1STK4STK3SIK2
Hydrochloric Acid SCHEMBL22191006 0.81 ERN1 (0.52) BRAFERN1STK4STK3SIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD BRAF 563/4885ERN1 3167/4885STK4 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.